Evidence map›Paper›PMID 34686234›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2021

Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.

F Stieber, J Howard, D Manissero, J Boyle, N Ndunda, J Love, M Yang, A Schumacher, R Uchiyama, S Parsons and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. QIAreach QuantiFERON-TB for the diagnosis ofThe European respiratory journal · 2022
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

F StieberQiagen Inc, Germantown, MD, USA.
J HowardQiagen Inc, Germantown, MD, USA.
D ManisseroQiagen Manchester Ltd, Manchester, UK.
J BoyleFormer Qiagen employee.
N NdundaFormer Qiagen employee.
J LoveFormer Qiagen employee.
M YangQiagen Inc, Germantown, MD, USA.
A SchumacherQiagen Inc, Germantown, MD, USA.
R UchiyamaQiagen Inc, Germantown, MD, USA.
S ParsonsEllume Limited, East Brisbane, QLD, Australia.
C MillerEllume Limited, East Brisbane, QLD, Australia.
H DouwesEllume Limited, East Brisbane, QLD, Australia.
Z MielensEllume Limited, East Brisbane, QLD, Australia.
T LaingEllume Limited, East Brisbane, QLD, Australia.
V NikolayevskyyQiagen Manchester Ltd, Manchester, UK, Imperial College, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Latent TuberculosisNanoparticlesHumansInterferon-gamma Release TestsMass ScreeningTuberculin Test

Identifiers

PMID34686234
PMCPMC8544925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.